MetaCap

Annexon (ANNX) vs Sagimet Biosciences Series A (SGMT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Sagimet Biosciences Series A (SGMT) has outperformed Annexon (ANNX) over the past year, gaining 36.1% versus a loss of 27.4%. Sagimet Biosciences Series A is the larger company by market cap ($648.0 million vs $591.4 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ANNX-27.40%SGMT+36.13%
+76%+20%-37%
Nov 21, 20251 yearNov 20, 2026
ANNX-15.76%SGMT-43.07%
+113%+8%-96%
Jul 10, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ANNX versus SGMT key metrics
MetricANNXSGMT
Share price$3.10$9.08
Market cap$591.37M$648.02M
1-day change-9.09%-5.61%
YTD return-38.25%+53.38%
1-year return-27.40%+36.13%
5-year return-77.37%—
EPS (TTM)$-1.01$-1.18
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-206.69M$-51.04M
52-week high$7.18$11.45
52-week low$3.07$4.50
Distance from 52-week high-56.82%-20.69%
Analyst consensusbuystrong_buy
Avg. price target upside+448.39%+200.33%
Average volume3.36M1.23M
Shares outstanding190.76M71.37M
Employees9716
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SGMT has outperformed ANNX by 63.5 percentage points over the past year.

About Annexon

ANNX stock →

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis.

Health Care · Biotechnology: Pharmaceutical Preparations · 97 employees

About Sagimet Biosciences Series A

SGMT stock →

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees

ANNX vs SGMT FAQ

Which is bigger, Annexon or Sagimet Biosciences Series A?

Sagimet Biosciences Series A (SGMT) is larger, with a market capitalization of $648.02M compared with $591.37M for Annexon (ANNX).

Which stock has performed better over the past year, ANNX or SGMT?

SGMT returned +36.13% over the past 12 months, compared with -27.40% for ANNX (price return, excluding dividends). Past performance does not predict future results.

Are Annexon and Sagimet Biosciences Series A in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons